Photodynamic therapy: A promising new modality for the treatment of cancer by Schuitmaker, J.J. (J.) et al.
Jt~raalof 
B:BIOLOGY 
ELSEVIER Journal of Photochemistry and Photobiology B: Biology 34 (1996) 3-12 
New Trends in Photobiology (Invited Review) 
Photodynamic therapy: a promising new modality for the treatment of 
cancer 
J.J. Schuitmaker a,* ,  p. Baas b, H.L.L.M. van Leengoed c, F.W. van der Meulen d, W.M. Star e, 
N. van Zandwijk b 
a Department ofOphthalmology, Academic Hospital of the University of Leiden, Sylvius Laboratory, Wassenaarseweg 72, 2333 AL Leiden, Netherlands 
b Department ofMedical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands 
c Department ofDermatology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263-0001 USA 
a Department ofOtolaryngology and Laser Centre, Academic Medical Centre, Meibergdreef9, 1105 Amsterdam, Netherlands 
Daniel den Hoed Cancer Centre, Department ofClinical Physics, PO Box 5201, 3008 AE Rotterdam, Netherlands 
Received 8 March 1996; accepted 3April 1996 
Abstract 
The first reports on photodynamic therapy (PDT) date back to the 1970s. Since then, several thousands of patients, both with early stage 
and advanced stage solid tumours, have been treated with PDT and many claims have been made regarding its efficacy. Nevertheless, the 
therapy has not yet found general acceptance by oncologists. Therefore it seems legitimate to ask whether PDT can still be described as 
"'a promising new therapy in the treatment of cancer". 
Clinically, PDT has been mainly used for bladder cancer, lung cancer and in malignant diseases of the skin and upper aerodigestive tract. 
The sensitizer used in the photodynamic treatment ofmost patients i  Photofrin®, (Photofrin®, the commercial name of dihematoporphyrin 
ether/ester, containing > 80% of the active porphyrin dimers/oligomers (A.M.R. Fisher, A.L. Murphee and C.J. Gomer, Clinical and 
preclinical photodynamictherapy, Review Series Article, Lasers Surg. Med., 17 (1995) 2-31 ). It is a complex mixture of porphyrins derived 
from hematoporphyrin. Although this sensitizer iseffective, itis not the most suitable photosensitizer fo PDT. Prolonged skin photosensitivity 
and the relatively low absorbance at630 rim, a wavelength where tissue penetration of light is not optimal, have been frequently cited as 
negative aspects hindering eneral acceptance. A multitude of new sensitizers i currently under evaluation. Most of these "second generation 
photosensitizers" are chemically pure, absorb light at around 650 nm or greater and induce no or less general skin photosensitivity. Another 
novel approach is the photosensitization f neoplasms by the induction of endogenous photosensitizers through the application of 5- 
aminolevulinic acid (ALA). This article addresses the use of PDT in the disciplines mentioned above and attempts o indicate developments 
of PDT which could be necessary for this therapy to gain a wider acceptance in the various fields. 
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1. Introduction 
Photodynamic therapy (PDT) has been designated as a 
"'promising new modality in the treatment of cancer" since 
the early 1980s. This can be partly attributed to the very 
attractive basic concept of PDT; the combination of two ther- 
apeutic agents, a photosensitizing drug and light, which are 
relatively harmless by themselves but combined (in the pres- 
ence of oxygen) ultimately cause more or less selective turn- 
our destruction. Nevertheless, PDT has not yet been widely 
accepted by practising oncologists. 
The clinical areas for which Photofrin®-based PDT has 
been predominantly used are superficial bladder cancer, lung 
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cancer and in cancer of the skin and upper aerodigestive tract. 
To date, this therapy has been approved in Canada for the 
prophylactic treatment of recurrent papillary bladder cancer 
and for the reduction of obstruction and palliation of dyspha- 
gia in patients with completely or partially obstructing oes- 
ophageal cancer. In the Netherlands it has been approved for 
obstructive, and early lung and oesophageal cancer and in 
Japan for early stage lung, gastric and cervical cancer (includ- 
ing cervical dysplasia), and superficial oesophageal nd gas- 
tric cancer. Recently, the US Food and Drug Administration 
(FDA) approved Photofrin® for palliative treatment of 
patients with totally obstructing tumors and partially obstruct- 
ing oesophageal cancers that are unsuitable for treatment with 
thermal laser therapy. The FDA approval includes clearance 
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for a number of specific laser systems and a fibre optic used 
to activate the sensitizer. 
Using a "standard" protocol (drug dose of 2-5 mg kg 
bw- l (bw, body weight) and 100-200 J cm -2, 24-72 h after 
intravenous administration) Photofrin® is an effective pho- 
tosensitizer in most cases. However, it is not the most suitable 
photosensitizer fo PDT due to the prolonged skin photosen- 
sitivity it induces and the relatively low absorbance at630 
nm, a wavelength where tissue penetration of light is not 
optimal. All patients who have received Photofrin® are pho- 
tosensitive and are usually advised to protect themselves from 
exposure to sunlight or bright lights for a period of four to 
eight weeks. Only a few studies have addressed this photo- 
sensitivity specifically. Most of these studies have been based 
on retrospective (by means of interview and/or question- 
naire) surveys [1 ], and follow-ups of treatments u ing rela- 
tively high drug doses [2,3]. Photosensitivity esting was 
reported in two studies. One was based on sequential weekly 
phototesting [4] but again using a relatively high drug dose 
(2-5 mg kg- 1 ). The second study showed adose-dependent 
relationship between drug dose and cutaneous photosensitiv- 
ity [ 5 ]. Therefore, it is to be expected that reducing the drug 
dose to 1 mg kg-~ [6], will reduce the duration of the cuta- 
neous photosensitivity. Apart from the kinetics of the pho- 
tosensitizer in the skin, the skin type and the compliance of 
the patient with the provided instructions will significantly 
influence the length and severity of the photosensitivity 
period. 
Second generation photosensitizers are chemically pure, 
absorb light at around 650 nm or longer and induce (with 
drug doses usually applied for PDT) no, or significantly ess, 
general skin photosensitivity. Increasing the wavelength at 
which sensitizers can be photoactivated not only allows the 
treatment of larger tissue volumes but also allows the possi- 
bility of using new light sources uch as light emitting diodes 
(LEDs) and laserdiodes. A few candidates currently under 
clinical investigation are: benzoporphyrin derivative mono- 
acid ring A (BPD-MA, A = 690 nm), mono-l-aspartyl chlorin 
e6 (NPe6, A=654 nm), tin ethyl etiopurpurin (SnET2, 
A=660 nm) and meta-tetra(hydroxyphenyl)chlorin (m- 
THPC, A = 652 nm). Apart from the properties mentioned, it 
must be proven for every new second generation photosen- 
sitizer that it is at least as efficient in eradicating tumors as 
Photofrin® which still must be viewed as the gold standard 
for photodynamic therapy. A recent development is the pho- 
tosensitization f tumors by endogenous induction of pho- 
tosensitizers through the topical or systemic application of 
5-aminolevulinic acid (ALA) [7]. ALA is the metabolic 
precursor of protoporphyrin IX (PplX) in the biosynthetic 
pathway to haem. In contrast to ALA, PplX is photodynam- 
ically active and so can act as an endogenous photosensitizer. 
High complete response rates and excellent cosmetic results 
have been reported, especially when treating superficial basal 
cell carcinomas in the head and neck region [ 8 ]. 
This article addresses the use of (mainly) Photofrin®- 
based PDT in superficial bladder cancer, lung cancer and in 
diseases of the skin and upper aerodigestive tract. Clinically, 
these are the areas for which this therapy has been chiefly 
used. Furthermore, an attempt will be made to indicate future 
developments of PDT which could be necessary for this ther- 
apy to gain a wider acceptance in the various fields. 
2. Photodynamic therapy of superficial bladder cancer 
2. I. Introduction and early clinical results 
Of patients diagnosed with bladder cancer, 75-80% ini- 
tially present with superficial tumours. The primary form of 
treatment is transurethral resection (TUR), but recurrences 
occur in 40-80% of cases. Intravesical chemotherapy or
immunotherapy (with Bacillus Calmette-Gu&in (BCG)) is 
applied to prevent or delay recurrence, with a 60-70% 
response rate [ 9]. Bladder cancers account for approximately 
3% of all malignant diseases. Of all bladder cancers, 75% are 
(uni) focal and show a low rate of progression, so that TUR 
is an adequate treatment. A small fraction (2%) is true car- 
cinoma in situ (CIS), which is resistant to conventional treat- 
ment modalities and has a high risk of progression. The 
remainder (23%) of patients has multifocal disease and CIS 
may also be present. 
Since visible light does not penetrate deeply into tissue, 
PDT is most effective in the treatment of superficial cancer. 
Therefore, PDT appears to be an attractive treatment alter- 
native for superficial bladder cancer. The initial experience 
with PDT in the bladder has been reviewed by a number of 
authors [10-12]. The first patients were treated with focal 
illumination, with good response rates, but it was soon real- 
ized that the potential of PDT would be optimally exploited 
only by whole bladder wall irradiation. The purpose of PDT 
treatment ofsuperficial bladder cancer is twofold: eradication 
of visible and invisible disease and prevention of recurrence 
after TUR. Basically, the whole bladder wall is at risk of 
developing new tumours. Therefore, a photosensitizer which 
is preferentially retained in malignant and pre-malignant tis- 
sue, combined with uniform irradiation of the bladder wall, 
could ideally yield complete tumour destruction with sparing 
of normal mucosa. In clinical practice, it has been found that 
whole bladder wall PDT can be effective against superficial 
bladder cancer, but the side effects are not negligible [13- 
17]. Apart from Photofrin® induced skin photosensitivity, 
the most important side effects are increased urinary fre- 
quency, urgency and bladder spasm. Reduction in bladder 
capacity is generally temporary. The most serious compli- 
cation is permanent bladder contraction, which is probably 
an indication of overdosage [ 12]. 
2.2. Light delivery and light dosimetry for whole bladder 
PDT 
The full potential of whole bladder PDT can only be 
achieved with optimum light delivery and light dosimetry. 
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The most common device for light delivery is a spherical 
diffuser mounted on the tip of an optical fibre connected toa 
laser. The diffuser should emit light uniformly in all direc- 
tions and should be placed at the centre of the bladder. This 
is usually done with the help ofintravesical ultrasound, which 
is not easy, since the bladder is not a sphere [ 18 ], this method 
~s not very sensitive and gives no information about he light 
Jistribution. A small displacement of the diffuser from the 
aptimum position can lead to a large non-uniformity in the 
light dose [19] which could cause complications [14]. 
Jocham, Uns61d and coworkers [13,20,21] have developed 
special catheters and balloons to ensure uniform light deliv- 
ery. Nseyo et al. [ 18] have developed a balloon that forces 
the bladder into a sphere with the diffuser at its centre. In this 
way uniform illumination is guaranteed. However, this does 
not guarantee that the same light dose is delivered to each 
patient because the scattered part of the light dose differs 
between patients. Marijnissen et al. [ 19] have developed a 
system providing in situ light dosimetry, for optimum place- 
ment of the diffuser and to measure the true light dose. Most 
authors have reported the light dose to the bladder wall in 
terms of non-scattered light, calculated from the power emit- 
ted by the diffuser. Clinical in situ measurements have shown 
a large effect of scattered light, so that the total light dose is 
an the average 5 times the non-scattered light dose. If the 
non-scattered light dose is reported to be 15 J cm z, then the 
true light dose is on average 75 J cm-2. A further complica- 
tion is that the contribution of scattered light differs between 
patients. The ratio between total and non-scattered light dose 
was found to vary between 2.5 and 7.1 [ 22] and these xper- 
imental data were confirmed by calculations using measured 
optical properties [23]. It thus appears that in situ light 
~losimetry is indispensable. 
after instillation of AIPcS [26] and Photofrin® [27]. 
Recently, endogenous photosensitization after application of 
5-aminolevulinic a id (ALA) has been used effectively in 
PDT of superficial human skin cancer [7]. Experimental 
results with rats indicate that this method may also be effec- 
tive in the bladder [28]. This was recently confirmed in 
clinical treatments ofpatients with superficial bladder cancer 
[29,30]. The side effects of PDT in the bladder, e.g. dysuria 
and pollakisuria, seem to be less after ALA-PDT rather than 
after Photofrin®-PDT. Reduction of bladder capacity has not 
yet been observed [29,30]. In summary; there are still many 
ways to improve PDT of bladder cancer. 
2.4. Detection of bladder cancer by photosensitizer 
induced fluorescence 
Since superficial bladder cancer is often not cystoscopi- 
cally visible, fluorescence detection based on preferential 
drug retention is very attractive. The usefulness of Photof- 
rin® fluorescence for cancer detection i the bladder has been 
demonstrated in both experimental nimals [31 ] and clini- 
cally [ 32]. Instillation of ALA is also very promising in this 
respect [33]. The sensitivity of ALA-induced fluorescence 
for detection of superficial bladder cancer is approaching 
100%, compared with 73% for white light cytoscopy. How- 
ever, ALA-induced fluorescence has not improved the spec- 
ificity (=65%) [34]. If the specificity of fluorescence 
cytoscopy can be improved, this method has potential for use 
in routine clinical practice. No other drugs have been studied 
for fluorescence d tection of bladder cancer. 
3. Photodynamic therapy of lung cancer 
2.3. Recent clinical results and possible improvements 3.1. Introduction 
Although there is agreement that PDT has potential in the 
treatment of superficial bladder cancer, recent long term fol- 
low-up results are no better than the instillation of BCG or 
chemotherapeutic drugs [13,17], not even when in situ 
,:losimetry was performed. Furthermore, the side effects are 
=onsiderable [ 24 ]. Thus the question arises whether the ther- 
apeutic ratio can be improved. One possibility is lowering of 
the administered Photofrin® dose, which is mostly 2 mg 
kg- 1. Studies on PDT of skin cancer have shown that 1 mg 
kg- ~ Photofrin® combined with a higher light dose yields 
an improved therapeutic ratio [ 7 ]. The same may be possible 
m PDT of bladder cancer. Recently, Jocham [25] has 
~lesigned a phase III study to compare PDT using 1.5 mg 
kg- ~ Photofrin® against instillation of BCG. The distribu- 
tion of sulphonated aluminium phthalocyanine (AIPcS) in 
rat bladder tissue suggests that PDT with this drug may yield 
a better therapeutic ratio than with Photofrin® [26]. Instil- 
lation of a photosensitizer in the bladder would avoid the 
problem of induced skin photosensitivity, but experiments 
suggest that the therapeutic effect of PDT is insufficient, both 
Despite major advances over the past 40 years in the field 
of surgery, radiation therapy and more recently chemother- 
apy, the failure rate of lung cancer treatment remains unac- 
ceptably high. One interpretation of the apparent lack of 
overall progress in recent years is that currently available 
approaches to lung cancer treatment are being used at close 
to optimal evels. In addition, efficient echniques for early 
diagnosis of local and metastatic (sub-clinical) disease are 
lacking. Virtually all approaches tofurther improve the treat- 
ment of lung cancer have been empirical and unfortunately 
there is still little collaboration between clinicians and basic 
scientists. In this respect, PDT is attractive [ 35 ] in that it 
requires only minimally invasive techniques (flexible bron- 
choscopy), it may be repeated several times and, apart from 
skin photosensitivity, is not accompanied bysignificant mor- 
bidity. It is estimated that more than one thousand lung cancer 
patients have been treated with PDT. The standard treatment 
protocol involves intraveneous (iv.) injection of a photosen- 
sitizing agent (usually Photofrin®, 2 mg kg-~ bw for lung 
cancer), followed 24-48 h later by exposure to laser light 
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(200--400 mW cm -~ diffuser, 100-200 J cm -1) at the 
activating wavelength. 
3.2. PDT in early stage lung cancer 
At the Tokyo Medical College Hospital, Kato et al. [36] 
used hematoporphyrin derivative (HPD) to treat 30 lesions 
in 26 patients with early stage (stage Ia according to the UKC 
classification) non-small cell lung cancer (NSCLC). All 
lesions showed a complete response after treatment as con- 
firmed by histology and cytology. Malignancy recurred in 
only three lesions. After an average follow-up period of 39.5 
months, 16 patients were alive and apparently free of disease, 
three having survived for more than five years and one for 
eight years. The best results were obtained in those patients 
where endoscopically the tumour appeared to be relatively 
small and confined to one or two (sub)segmental bronchi 
[37]. 
In the Mayo Clinic, 13 patients presenting with NSCLC 
were considered surgical candidates before PDT was per- 
formed [38-40]. The patients were treated with the under- 
standing that if there was residual cancer after no more than 
two sessions of PDT, performed at three month intervals, 
they would receive surgical therapy. In this group of 13 
patients, 12 (92%) achieved a complete response. Ten 
(76%) revealed a complete response after the first photody- 
namic treatment, wo other patients after the second treat- 
ment. Of the 12 lesions in which a complete response was 
obtained, three (25%) recurred uring the first two years of 
follow-up. Two of them could be surgically resected and one 
underwent a third PDT treatment and demonstrated, again, a 
complete response. 
At the Netherlands Cancer Institute, 10 out of 11 patients 
with stage I NSCLC achieved a complete response with PDT 
(using Photofrin®) [41]. The only remaining patient 
achieved a partial response, still showing carcinoma in situ 
after a second treatment. This series of patients was not 
restricted to "early stage" patients and differed from the 
Mayo series in that 10 out of 11 cases were not considered 
surgical candidates as a consequence of poor pulmonary 
function. 
A recent publication on PDT in early stage lung cancer 
from Furuse et al. [42] confirms the excellent effects of PDT 
in 54 patients with centrally located early stage lung cancer, 
who have limited tumour invasion extending over a small 
area of the bronchial tree (preferably < 1 cm). With the pres- 
ent technology, the indication for PDT in early stage lung 
cancer may be summarized according to Kato [42]: "the 
lesion should be visible endoscopically and it should be pos- 
sible to recognize the peripheral margin of the tumour, 
submucosal tumour invasion should be limited to within 
the bronchial cartilage and the lesion should be able to be 
photoirradiated from a 90 ° angle". 
3.3. PDT in advanced lung cancer 
The results of the series of patients with advanced locore- 
gional disease reported so far are more difficult o interpret. 
By definition they include patients with a variety of prognos- 
tic factors uch as all kinds of combinations of tumour and 
lymph node (TN) status, performance score and weight loss. 
During follow-up, a significant proportion of the test popu- 
lation will also present with distant metastases, in some cases 
shortly after locoregional treatment. Local control can not be 
evaluated as rigidly and survival figures hould be interpreted 
with caution. Moreover, the assessment of response in 
patients with advanced isease is quite complicated. It is 
frequently hampered by the difficulties of combining the out- 
come of chest roentgenology (including CT-scan) with the 
results obtained by bronchoscopy. Nevertheless, in all series 
(partial) response rates are fairly high [43]. 
Major complications associated with PDT have been 
encountered in two categories of patients. Massive haemop- 
tysis has been observed in patients with large obstructive 
tumours. Some of these patients had also received previous 
treatments such as radiotherapy orNd-YAG laser treatment, 
both of which probably have contributed to the normal 
tissue damage. In a group of 26 patients, Sutedja et al. [41 ] 
encountered four who suffered from pulmonary haemorrhage 
at times varying from 1.5 months to 6 months after treatment. 
Each of the patients uffered from tumour progression atthe 
time of bleeding and the authors could not attribute these 
haemorrhages to PDT alone [41]. The second major com- 
plication (respiratory distress) observed in patients whose 
pulmonary reserve was seriously limited can be prevented by 
careful selection of patients [ 39]. The PDT treatment causes 
edema nd sometimes obstruction of the airway by swelling 
of necrotic tumour. There is a clear need for the removal of 
this necrotic debris, preferably within two days after illumi- 
nation. The majority of patients that suffer from a limited 
pulmonary reserve as a consequence of pneumonectomy 
should not be treated with PDT. However, PDT either as a 
single therapeutic method or in addition to surgery, has a 
place in the treatment of other patients with limited cardio- 
pulmonary reserves (not resulting from pneumonectomy), 
allowing for maximal preservation fpulmonary function. 
Careful protection and explicit instruction to avoid sunlight 
have decreased the frequency of general skin photosensitiv- 
ity, which was initially reported to occur in 25-35% of 
the patients [44]. Almost all patients are able to resume 
normal daily activity, 4 to 8 weeks after injection of 
hematoporphyrin. 
4. Photodynamic therapy for the treatment of 
malignant and non-malignant skin diseases 
4.1. Introduction and early clinical results 
Skin cancer is by far the most common of all malignancies. 
In the United States alone there are more than 800,000 new 
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non-melanoma skin cancers each year. The incidence isrising 
with the current generation's pattern of increasing recrea- 
tional sun exposure, and also with the decrease in protection 
by the ozone layer in the atmosphere. For the treatment of 
these malignancies, there are several existing therapeutic 
modalities. These include (in order of decreasing efficacy) 
Moh's surgery, conventional excisional surgery, radiation 
therapy, curettage and electrodesiccation, a d cryotherapy. 
Unfortunately these therapies also have drawbacks. They 
often cause significant morbidity (both in healing, and in 
cosmetic or functional outcome) and they usually have lim- 
itations in the ability to treat multiple lesions with high effi- 
cacy. Finally, treatment can be expensive. 
Over the past 10 years, PDT with systemic Photofrin® has 
been used for multiple types of cutaneous and subcutaneous 
malignancies including basal cell carcinoma [7,45], wide- 
spread Bowen's disease [45--47], squamous cell carcinoma 
[48-52], metastatic and recurrent breast carcinoma 
[50,51,53-55] and Kaposi's sarcoma [56]. In a few 
instances PDT has also been used for palliation of metastatic 
melanoma [ 50,51,54 ]. There is also experience with PDT on 
patients with non-malignant lesions uch as psoriasis [ 57,58 ]
as an alternative to psoralen UVA and encouraging results 
have been reported on the treatment of laryngeal warts [59]. 
By far, basal cell carcinomas have been the most numerous 
of all tumours treated with PDT. Unfortunately between the 
various studies reported, the treatment parameters such as 
drug dose, light dose, anatomical location and histological 
type have varied greatly. Nevertheless, for primary lesions 
revolving the skin, investigators eport high ()80%) com- 
plete response rates that are often durable, combined with 
~xcellent cosmetic results. 
4. 2. Topical photosensitizer application 
The skin is the largest organ of our body. It is readily 
accessible to the light that is required for photosensitizer 
activation and also permits the use of a topical formulation 
,)f a photosensitizer. In this way, treatment selectivity can be 
:naximized and the general skin-photosensitivity associated 
~vith the use of Photofrin® avoided. Tetraphenylporphine- 
~:etrasulphonate (TPPS4) has been evaluated for this purpose. 
~, complete response rate of 93.5% and a two year ecurrence 
rate of 18-20% has been reported [60]. Currently the focus 
"or topical photosensitizers is on ALA. ALA is the metabolic 
!grecursor to protoporphyrin IX (PplX) in the biosynthetic 
,0athway for haem. In contrast to ALA, PplX is photodyn- 
amically active and so can act as an endogenous photosen- 
.;itizer. Because of its high polarity, topical application of 
~,LA will result in an increased penetration i  abnormal skin, 
where the stratum corneum isdamaged, as opposed to normal 
.&in with an intact stratum corneum. Depending on the rate 
ff conversion of ALA to PplX and similarly of PplX to haem, 
a temporary accumulation of the photosensitizer can occur. 
Numerous investigators have examined topical ALA-PDT 
ior superficial carcinomas with varying degrees of success 
ranging from 50% to almost 100% [61--66]. The differences 
in response rates are probably due to differences in treatment 
protocol and patient selection criteria. Topical therapy seems 
to be less effective on thick lesions, or those which are cov- 
ered by a layer of normal epidermis [61,63]. In such cases 
multiple treatments with ALA-PDT may be effective [64]. 
An interesting new development is the use of ALA-PDT for 
cutaneous T-cell lymphoma [64,67] aimed at selectively 
clearing skin of malignant lymphocytes. 
5. Photodynamic therapy in the treatment of upper 
aerodigestive tract disease 
5.1. Introduction and first clinical results 
In the upper aerodigestive tract, PDT is used for treatment 
of malignant neoplasms and occasionally for benign lesions 
such as papillomas of the larynx. The former comprise about 
5% of all malignancies in Western Caucasian people and 
consist, for ninety percent, of squamous cell carcinomas aris- 
ing from the surface pithelium [68]. The maximum inci- 
dence occurs between 50 and 70 years of age and intake of 
alcohol and tobacco consumption are recognized as facilitat- 
ing etiologic factors [69 ]. This also implies that in some of 
these patients, the whole mucosal lining of the upper aero- 
digestive tract is "condemned" and frequently deteriorates 
into cancer, so-called "field cancerization" [70]. Further- 
more, in 10-20% of the patients treated for primary carci- 
noma, secondary malignancies in the head and neck area can 
be detected at the time of first treatment or during follow up 
[ 71,72 ]. Most of these so-called "secondaries" are detected 
in the early stage, e.g. carcinoma in situ or microinvasive 
carcinoma [73]. 
Traditionally the therapy of head and neck cancer consists 
of surgery and/or adiotherapy and gives an overall cure rate 
of only 55-65%. In addition to these low cure rates, the 
interventions often cause serious mutilation. Therefore, there 
is a continuing search for other, effective and less mutilating 
therapeutic modalities. Can PDT offer a meaningful contri- 
bution in this field? 
The first report of PDT for head and neck cancer dates 
from 1982. Wile and coworkers [74] described a 75% (com- 
plete and partial) response of locally recurrent carcinomas 
located on various ites in the upper aerodigestive tract. After 
previous radiotherapy, areas treated with PDT healed well 
and even repeated applications of this treatment were toler- 
ated well. Bulky tumours howed a lower cure rate [75,76]. 
The most favourable r sponses were obtained in early super- 
ficial disease, whereas neck metastases responded poorly 
[77 ]. Good palliation and an occasional cure were described 
by some authors in cases of advanced local recurrence [ 78 ], 
others could not confirm the role of PDT as a valuable tool 
for palliation [79], however, treatment of condemned 
mucosa ppeared to be successful [79]. Small carcinomas in
the oral and oropharyngeal regions (frequently recurrent dis- 
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ease) had a tendency to regrow after PDT, possibly as a 
consequence of underestimation of tumour infiltration [79]. 
In a series of PDT treatments of vocal cord carcinoma with 
involvement of one side only, a response rate of 72% was 
achieved uring a follow up of 1-4 years [80]. Monnier et 
al. [81] and Moghissi et al. [82] obtained good results with 
photodynamic therapy in the treatment of very superficial 
lesions such as carcinoma in situ and microinvasive carci- 
noma. In geometrically complex locations where homoge- 
neous illumination of the target area is difficult to achieve, 
the rate of recurrence increases. To avoid an insufficient light 
dose, Biel et al. treated tumours of 3 mm in thickness or more 
with interstitial PDT, often in conjunction with surface illu- 
mination [ 83]. Overall it appears that good estimation of 
tumour thickness, proper exposure of the target volume and 
great care in light dosimetry and drug dosage are the most 
important factors to determine success or failure of PDT in 
the upper aerodigestive tract. 
Monnier et al. [ 81 ] reported on PDT-induced tissue dam- 
age in normal mucosa which received a rather low drug/light 
dose; in addition, some cases were reported of cicatricial 
stenosis and fistula attributable tothe lack of tumor selectivity 
of HpD. Using a dose of 2 mg kg- l bw ~ i.v. Photofrin®, 
Overholt et al. showed that it is possible to induce selective 
necrosis of mucosa without damaging the underlying muscle 
[ 84]. PDT used in this way may have potential for treatment 
of large areas of dysplasia s in Barret's oesophagus. In this 
disease, which is caused by gastro-oesophageal r flux, there 
is a metaplastic change from squamous epithelium to colum- 
nar epithelium in the lower oesophagus. It is regarded as a 
premalignant condition, particularly if dysplasia is present 
[85]. As only the mucosa is affected (so the problem is 
limited in depth) PDT can offer an attractive alternative for 
radical oesophageal resection. Using Photofrin® (2 mg kg. 
bw- l) or ALA (60 mg kg- 1 bw- ~ orally) and optical irra- 
diation with light of 630 nm (100-200 J cm-2), treatment 
resulted in partial, sometimes complete replacement of Bar- 
ret's mucosa with normal squamous epithelium [84,86]. 
Whether the cancer isk is also removed by PDT treatment 
of Barret's oesophagus remains to be established. 
5.2. New sensitizers 
A number of second generation photosensitizers have 
already been applied in PDT for head and neck cancer. Savary 
et al. [87] presented preliminary results obtained with meta- 
tetrahydroxyphenyl ch orin (m-THPC). m-THPC has an 
absorption peak at 652 nm. It is effective at low drug and 
light doses eg. 10 J cm -2, 48 h after i.v. administration of
0.3 mg kg- ~ bw 1. Based on fluorescence microscopy stud- 
ies of biopsies of healthy mucosa nd early upper aerodiges- 
tive cancer, a delay of four days between drug delivery and 
illumination was suggested to obtain an optimal tumour/ 
normal tissue ratio of m-THPC. 16 early carcinomas in the 
upper aerodigestive tract were treated with m-THPC: 14 
lesions showed acomplete response without regrowth in a 6 
months follow-up [ 88 ]. In addition, subsequent skin photo- 
sensitivity was 6 weeks at the most. m-THPC can be activated 
at a number of wavelengths eg. 514 and 652 nm. At the same 
light and drug dose, the latter wavelength may cause deeper 
necrosis by its deeper tissue penetration i  combination with 
the larger molecular absorption coefficient of m-THPC at 652 
nm, as compared with 514 nm. Using m-THPC and light of 
wavelength 652 nm in a patient with superficial carcinoma in
the oesophagus, led to the development of an oesophago- 
tracheal fistula. For a more superficial effect 514 nm illumi- 
nation seems to be preferable [89]. In testing the normal 
tissue tolerance, Monnier et al. reported a wide inter-individ- 
ual variation in tumour esponse and in the duration of skin 
photosensitivity. A multicentre European study to evaluate 
the application of m-THPC in PDT of early head and neck 
cancer is presently being organized [90]. 
Photosensitization by the endogenous production of pro- 
toporphyrin IX (PplX) through administration of ALA has 
also been applied in head and neck surgery on an experimental 
basis. Topical application of ALA on skin tumours led to the 
production of sufficient PplX to induce a tumouricidal effect 
following illumination with light of 630 nm [ 61 ]. After oral 
administration fALA to patients with squamous cell carci- 
nomas of the oral cavity, maximal fluorescence of tumour 
and dysplastic epithelium occurred 4 to 6 hours after admin- 
istration. Necrosis of malignant tissue in response to ALA- 
PDT was apparent [91]. The same group also reported on 
the PDT of severe dysplasia nd intraepithelial carcinomas 
of the oral cavity with orally administered ALA. In 10 
patients, they demonstrated full thickness epithelial necrosis 
and subsequent good healing following illumination [92 ]. In 
both reports, a transient rise of liver enzymes as a result of 
oral ALA was reported, returning to a normal evel within 
seven days. The main advantage of using oral ALA induced 
PplX photosensitization is the rapid clearance of the sensitizer 
( 1-2 days). This way, repeated treatments using short time 
intervals might be feasible. 
5.3. Other applications 
Intraoperative photodynamic therapy (IOPDT) [78] has 
shown to result in larger tumour-free margins in case of min- 
imal persistent or residual disease after ablation [93,94]. In 
5 patients, all of whom had previously undergone extensive 
conventional treatment, PDT of the entire tumour esection 
bed was performed intraoperatively. The irradiated areas 
included the carotid artery and the internal jugular vein. All 
uninvolved skin was covered and excessive exposure to light 
by operating theatre lamps was avoided by using surgical 
head-mounted lamps during the surgical resection. Healing 
occurred without complication and preliminary results indi- 
cate a disease-free follow-up of 18 months in all cases [94]. 
Besides quamous cell carcinomas, other malignancies in
the upper aerodigestive tract have also been treated with PDT. 
Five patients with Kaposi' ssarcoma of the oral cavity causing 
symptoms of dysphagia nd interference with speech were 
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treated with PDT using Photofrin®. Surface illumination as 
well as interstitial photodynamic therapy were used. All 
patients achieved symptomatic relief, three of them showing 
a complete remission during 3-7 months [56 ]. Additionally, 
the use of PDT was mentioned in three cases of mucosal 
melanomas of the upper aerodigestive tract. Using interstitial 
and surface illumination, no local regrowth was noticeable 
during the observation period of 12-18 months [83 ]. 
Occasionally, PDT has been applied in benign disease such 
as recurrent laryngeal papillomatosis [95]. Recent reports 
indicate variable fficacy for PDT in this disease. During a 
four year follow-up more than half of a group of 25 patients 
remained free of relapse of these virally induced lesions 
[96,97]. Biel et al. however, mentions a recurrence rate of 
100% in five patients [83]. 
6. Summary and perspectives 
Photofrin® based PDT of superficial bladder cancer has 
severe side effects and long term follow-up results are at 
present no better than for conventional methods. However, 
there are many ways to improve xisting treatment protocols. 
Permanent bladder contraction may be prevented by optimiz- 
ing therapeutic ratios by lowering the Photofrin® dose from 
2 to 1.5, or even 1 mg kg- i bw- ~ and by standardized appli- 
cation of in situ dosimetry. Improvement of therapeutic ratios 
however, may also be obtained by using second generation 
photosensitizers. Photosensitization by installation of ALA 
is very promising in this respect. In addition, topical appli- 
cation of a photosensitizer to some extent circumvents he 
regulatory problems associated with the intravenous admin- 
istration of a new drug. 
For early-stage lung cancer, Photofrin® based PDT is a 
new addition to the standard treatment modalities of surgical 
resection, radiation therapy and chemotherapy. In the treat- 
ment of carcinoma in situ or in treating endobronchial 
NSCLC in the intramural stage it can be curative. This implies 
that a more widespread adoption of PDT in the field of lung 
cancer (but not only there) may depend - at least in part - on 
screening and early detection of malignant neoplasms. Fur- 
thermore, the medical awareness of the tissue sparing prop- 
erties of this therapy should be enhanced. 
In advanced lung or oesophageal cancer, PDT is associated 
with major complications and is currently at best palliative. 
In patients with high surgical risk it can provide an alternative 
to surgical resection or it can diminish the size of resection. 
Controlled studies are needed to determine whether the long 
term curative potential of the treatment will be equivalent to 
that of surgical resection. However, endobronchial obstruc- 
tion is a common complication of advanced-stage NSCLC. 
Significant relief is possible with PDT but, due to extensive 
tumour load, cure can not be expected in this group of 
patients. 
The results of PDT in the treatment ofmalignant and non- 
malignant skin diseases are most encouraging and, using 
either systemic or topical photosensitizer formulations, this 
therapy has the potential of becoming the treatment ofchoice. 
High complete response rates are reported and cosmetic 
results especially are often superior to conventional treatment 
methods. Investigators agree that there is minimal dermal 
damage and little or no scarring. Improvement of the therapy 
in this field is primarily sought in decreasing the overall skin 
photosensitivity after intravenous administration of Photof- 
rinD. However, for PDT to become accepted in this field it 
will have to prove its cost effectiveness in the competition 
with traditional modalities such as cryo-surgery, excision and 
curettage/electrodesiccation. 
Conventional treatment of head and neck cancer often 
leads to mutilation. A treatment which effectively eradicates 
tumours without leaving defects and scars would be an impor- 
tant expansion of the oncologist's armamentarium. The main 
indication of PDT in the management of head and neck malig- 
nancies today is the treatment ofsuperficial disease, e.g. con- 
demned mucosa and intraepithelial or microinvasive 
carcinoma. Furthermore T1 and T2 carcinomas, as well as 
superficial recurrences after previous therapy, can be treated 
but only if reliable information concerning infiltration depth 
of the tumour, good exposure of the treatment site, adequate 
light delivery and light and drug dosimetry isavailable. Then, 
the advantages of PDT, such as complete restoration of the 
tissues involved and the possibility to repeat he treatment 
will prevail. In geometrically complex regions the efficacy of 
PDT diminishes due to complicated dosimetry. Although the 
anecdotal data are promising, PDT still has to prove itself 
more effective in the management of head and neck malig- 
nancies than existing therapies, preferably in randomized 
clinical trials. 
General acceptance of PDT by most oncologists has been 
(and is) hampered for v~trious reasons: 
(i) Photodynamic therapy must fit into the specific "cul- 
ture" of the hospital. The difficulties associated with the 
development of a new research line in a clinical setting are 
numerous. 
(ii) PDT is especially suited for treatment ofearly lesions. 
Therefore, the number of patients eligible for PDT will 
increase provided the early detection of malignancies 
improves. Early lesions are in most cases difficult to detect 
and large-scale screening requires a considerable effort in 
manpower and money [98]. 
(iii) Illumination after administration of the photosensi- 
tizer requires a medical dye-laser. These devices are very 
expensive, large, and use and maintenance necessitate he 
presence of a skilled technician. Furthermore, the complexity 
of proper light delivery (device-to-fibre coupling, in vitro 
and in vivo light dosimetry, light scattering properties of 
various tissues) must not be underestimated. 
(iv) A suitable photosensitizer (a pure, single chemical 
substance, easily and consistently manufactured which 
does not induce skin phototoxicity) for PDT, approved by 
regulatory agencies uch as the FDA is not yet available. 
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Nevertheless, there are arguments to give an affirmative 
answer to the question whether PDT still can be called "a 
promising new modality". First, the basic concept of PDT, 
combining two modalities which are harmless by themselves 
to obtain a beneficial therapeutic effect, remains attractive. 
Secondly, there is no significant morbidity associated with 
PDT; especially not when second generation photosensitizers 
are used. Wound healing, functional and cosmetic outcome 
after PDT are often superior to established therapies. Thirdly, 
every year a large number of new drugs are advanced as 
potential new photosensitizers in clinical photodynamic ther- 
apy. Although the majority of these new drugs will never 
enter widespread clinical practice, it is certain that he current 
second generation of photosensitizers will not be the last. 
Regarding the complex and expensive laser systems needed 
for illumination: it is clear that light application eeded for 
treatment will have to move into the field of cheaper and less 
complicated, user-friendly ight sources uch as diode lasers 
and non-coherent light sources optimized for PDT. In view 
of the rapid developments in optoelectronics t is reasonable 
to assume - especially if there is a demand from the market - 
that within the next decade laserdiodes will be available cov- 
ering the spectrum from UV to IR at very competitive prices. 
The developments could be such that in the foreseeable 
future, a clinician may choose from a variety of photosensi- 
tizers and devices, the most optimal combination to treat he 
malignancy with which he is confronted. 
Finally, PDT offers a badly needed new approach in oncol- 
ogy, a field in which established therapies operate close to 
optimal levels. As for all new treatment modalities, PDT has 
to prove itself equal (at least) or superior to existing thera- 
pies, preferably in randomized clinical trials. A cost-effect- 
iveness tudy should be an integral part of these trials. In view 
of the low cost of diode lasers (as compared to more conven- 
tional clinical laser systems) and provided that the price of 
the next generation of photosensitizers will be reasonable, 
PDT could develop into a very cost effective treatment. Not 
only in oncology but very likely also in ophthalmology for 
treatment of macular degeneration a d possibly in dermatol- 
ogy for psoriasis and in immunology for the treatment of 
autoimmune diseases [ 99]. 
However, now the FDA has (finally) approved Photof- 
rin® for the largest pharmaceutical market in the world, the 
US, it is of the utmost importance for the survival of PDT 
that this therapy proves its right to exist as an established 
therapy in a clinical setting within the next five to 10 years. 
References 
[ 1 ] T.J. Dougherty, W.R. Potter and D. Bellnier, Photodynamic therapy 
for the treatment of cancer: Current status and advances, In D. Kessel 
(ed.), Photodynamic Therapy of Neoplastic Disease (Vol. 1), CRC 
Press, Boca Raton, FL, 1990, pp. 1-19. 
[2] R.S. Wooten, K.C. Smith and D.A. Ahlquist, Prospective study of 
cutaneous phototoxicity after systemic hematoporphyrin derivative, 
Lasers Surg. Med., 8 (1988) 294-300. 
[3] V.M. Mullooly, A.L. Abramson and M.J. Shikowitz, Dihemato- 
porphyrin-ether induced photosensitivity in laryngeal papilloma 
patients, Lasers Surg. Med., 10 (1990) 349-356. 
[4l N. Razum, O.J. Balchum, A.E. Profio et al., Skin photosensitivity: 
Duration and intensity following intravenous hematoporphyrin 
derivatives, HPD and DHE, Photochem. Photobiol., 46 (1987) 925- 
928. 
[5] S. Lam, B. Palcic, D. McLean et al., Detection of early lung cancer 
using low dose Photofrin II, Chest, 97 (1990) 333-337. 
[6] B.D. Wilson, T.S. Mang, H. Stoll, C. Jones, M. Cooper and T.J. 
Dougherty, Photodynamic therapy for the treatment of basal cell 
carcinoma, Arch. Dermatol., 128 (1992) 1597-1601. 
[7] J.C. Kennedy and R.H. Pottier, Endogenous protoporphyrin IX, a 
clinically useful photosensitizer for photodynamic therapy, J. 
Photochem. Photobiol. B: Biol., 14 (1991) 275-292. 
[ 8 ] A.M.R. Fisher, A.L. Murphree and C.J. Gomer, Clinical and preclinical 
photodynamic therapy, Rev. Set., Lasers Surg. Med., 17 ( 1995 ) 2-31. 
[91 B.J. Lure and F.M. Torti, Adjuvant intravesicular pharmacotherapy for 
superficial bladder cancer, J. Natl. Cancer Inst., 83 ( 1991 ) 682-694. 
[10] M.J. Manayak, Photodynamic therapy: principles and urologic 
applications, Semin. Urol., 9 (1991) 192-202. 
[ 11 ] A.J. Pope and S.G. Bown, Photodynamic therapy, Br. J. Urol., 68 
(1991) 1-9. 
[ 12 ] U.O. Nseyo, Photodynamic therapy, Urol. Clin. North Am., 19 (1992) 
591-599. 
[ 13 ] D. Jocham, M. Beer, R. Baumgartner, G. Staehler and E. Uns61d, Long- 
term experience with integral photodynamic therapy of TIS bladder 
carcinoma, in G. Bock and S. Harnet (eds.), Photosensitizing 
Compounds: their Chemistry, Biology and Clinical Use, Ciba 
Foundation Symposium 146, Wiley, Chichester, 1989, pp. 198-208. 
[ 14] J.l. Harty, M. Amin, T.J. Wieman, M.T. Tseng, D. Ackerman and W. 
Broghamer, Complications of whole bladder dihematoporphyrin ether 
photodynamic therapy, J. Urol., 141 (1989) 1341-1346. 
[15] K. Naito, H. Hisazumi, T. Uchibayashi, T. Amano, A. Hirata, K. 
Komatsu, T. Ishida and N. Miyoshi, Integral laser photodynamic 
treatment of refractory multifocal bladder tumours, J. UroL, 146 
(1991) 1541-1545. 
[ 16] M.A. D'Hallewin, L. Baert, J.P.A. Marijnissen and W.M. Star, Whole 
bladder wall photodynamic therapy with in situ light dosimetry for 
carcinoma in situ of the bladder, J. Urol., 148 (1992) 1152-1155. 
[ 17] T. Uchibayashi, K. Koshida, K. Kunimi and H. Hisazumi, Whole 
bladder wall photodynamic therapy for refractory carcinoma in situ of 
the bladder, Br. J. Cancer, 71 (1995) 625-628. 
[18] U.O. Nseyo, S.L. Lundahl and D.C. Merrill, Whole bladder 
photodynamic therapy: critical review of present-day technology and 
rationale for development of intravesical laser catheter and monitoring 
system, Urology, 36 (1990) 398-402. 
[ 19] J.P.A. Marijnissen, H. Jansen and W.M. Star, Treatment system for 
whole bladder wall photodynamic therapy with in vivo monitoring and 
control of light dose rate and dose, J. Urol., 142 (1989) 1351-1355. 
[20] E. Uns61d, W. Beyer, A. Heinze and R. Sroka, Irradiation modalities 
for photodynamic therapy, Lasers Med. Sci. Suppl. (1989) 159-164. 
[21] E. Uns61d, R. Baumgartner, W. Beyer, D. Jocham and H. Stepp, 
Fluorescence detection and photodynamic treatment of 
photosensitized tumours in special consideration of urology, Lasers 
Med. Sci., 5 (1990) 207-212. 
[22] J.P.A. Marijnissen, W.M. Star, H.J.A. in 't Zandt, M.A. D'Hallewin 
and L. Baert, In situ light dosimetry during whole bladder wall 
photodynamic therapy: clinical results and experimental verification, 
Phys. Med. Biol., 38 (1993) 567-582. 
[ 23 ] H.J. van Staveren, J.F. Beek, J.W.H. Ramaekers, M. Keijzer and W.M. 
Star, Integrating sphere effect in whole bladder wall photodynamic 
therapy. I: 532 nm versus 630 nm optical irradiation, Phys. Med. Biol., 
39 (1994) 947-959. 
[24] M.A. D'Hallewin and L. Baert, Long term results of whole bladder 
wall photodynamic therapy for carcinoma in situ of the bladder, 
Urology, 45 (1995) 763-767. 
J.J. Schuitmaker tal. / Journal of Photochemistry and Photobiology B: Biology 34 (1996) 3-12 11 
[25 ] D. Jocham, personal communication, 1996. 
[26] A.J. Pope and S.G. Bown, The morphological nd functional changes 
in rat bladder following photodynamic therapy with phthalocyanine 
photosensitization, J. Urol., 145 ( 1991 ) 1064-1070. 
[27] K. Taari, M. Talja, M. Riihel/i, S. Ranniko and R. Mokka, 
Morphological effects of photodynamic therapy on rabbit bladder 
using Photofrin II and Photosan intravesically and intravenously, Br. 
J. Urol., 70 (1992) 616---621. 
128] M. Kriegmair, R. Baumgartner, S. Stocker, R. Riesenberg, A. 
Hofstetter, R. Kn/ichel and P. Steinbach, Photodynamic therapy of 
urothelial cancer following intravesical application of 5- 
aminolevulinic acid in a rat bladder tumour model, J. Urol., 151 
(1994) 518A. 
29] M. Kriegmair, R. Baumgartner, W. Lumper, R. Waidelich, A. 
Hofstetter, Early clinical experience with 5-aminolevulinic a id for 
photodynamic therapy of superficial bladder cancer, submitted to Br. 
J. Urology. 
30] I. Eder, A. Stenzl, H. Kostron, G. Bartsch, H. Klocker, Elektromotive 
diffusion (EMD) and photodynamic therapy with 6-aminolevulinic 
acid (ALA) for superficial bladder cancer, J. Urology, 153 (1995) 
234A. 
31 ] R. Baumgartner, H. Fisslinger, D. Jocham, H. Lenz, L. Ruprecht, H. 
Stepp and E. Unst~ld, A fluorescence imaging device for endoscopic 
detection of early stage cancer-instrumental and experimental studies, 
Photochem. Photobiol., 46 (1987) 759-763. 
132] L. Baert, R. Berg, B. van Damme, M.A. D'Hallewin, J. Johansson, K.
Svanberg and S. Svanberg, Clinical fluorescence diagnosis of human 
bladder carcinoma following low dose Photofrin injection, Urology, 
41 (1993) 322-330. 
!i 33 ] M. Kriegmair, R. Baumgartner, W. Lumper, R. Riesenberg, S. Stocker 
and A. Hofstetter, Fluorescence cystoscopy following intravesical 
instillation of aminolevulinic aid (ALA), J. Urol., 149 ( 1993 ) 240A. 
34] M. Kriegmair, R. Baumgartner, R. Kniichel, H. Stepp, F. Hofst/idter, 
A. Hofstetter, Detection of early bladder cancer by 5-aminolevulinic 
acid induced porphyrin fluorescence, J. Urology, in press. 
35] J.B. Mitchell et al., Biological basis for phototherapy, in G. Morstyn 
and A.H. Kaye (eds.), Phototherapy ofCancer, Harwood Academic 
Publishers, Chur, 1990, pp. 1-22. 
36] H. Kato et al., Photodynamic therapy of early-stage lung cancer, in 
G. Bock and S. Harriet (eds.), Photosensitizing compounds: their 
chemistry biology and clinical use, Ciba Foundation Symposium 146, 
Wiley, Chichester, 1989, pp. 183-194. 
37] H. Kato, Photodynamic therapy of early cancer, in G. Morstyn, 
A.H. Kaye, (eds.), Phototherapy of Cancer, Harwood Academic 
Publishers, Chur, 1990, pp. 133-151. 
38] D.A. Cortese and J.H. Kinsey, Endoscopic management of lung cancer 
with hematoporphyrin derivative phototherapy, Mayo Clin. Proc., 57 
(1982) 543-547. 
39] E.S. Edell and D.A. Cortese, Bronchoscopic phototherapy with 
hematoporphyrin derivative for treatment of localized bronchogenic 
carcinoma:  five-year experience, Mayo Clin. Proc., 62 (1987) 8-14. 
i40] E.S. Edell and D.A. Cortese, Bronchoscopic localization and treatment 
of occult lung cancer, Chest, 96 (1989) 919-924. 
41 ] G. Sutedja, P. Baas, F.A. Stewart and N. van Zandwijk, A pilot study 
of photodynamic therapy in patients with inoperable non-small cell 
lung cancer, Eur. J. Cancer, 28a (1992) 1370-1373. 
42] K. Furuse, M. Fukuoka, H. Kato et al., A prospective phase II study 
on photodynamic therapy with Photofrin 1I for centrally located early- 
stage lung cancer, J. Clin. OncoL. 11 (1993) 1852-1857. 
43 ] N. van Zandwijk, T. Sutedja, P. Baas and F. Stewart, An emerging role 
for photodynamic therapy in lung cancer, Form. Trends Exp. Clin. 
Med., 3 (1993) 33-39. 
44] T.J. Dougherty et al., Cutaneous phototoxic occurrences in patients 
receiving photofrin, Lasers Surg. Med., 10 (1990) 485-488. 
45]  J.S. McCaughan, J.T. Guy, W. Hicks, L. Laufman, T.A. Nims and J. 
Walker, Photodynamic Therapy for Cutaneous and Subcutaneous 
Malignant Neoplasms, Arch. Surg., 125 (1989) 211-216. 
[46] P.J. Robinson, J.A.S. Carruth and G.M. Fairris, Photodynamic therapy: 
a better treatment for widespread Bowen's disease, Br. J. Dermatol., 
119 (1988) 59-61. 
[47] C. Jones, M. Cooper, T. Mang, B.D. Wilson and H.L. Stoll, 
Photodynamic Therapy in the Treatment ofUnusual Bowen's Disease, 
J. Am. Acad. Dermatol., 27 (1992) 979-982. 
[ 48 ] B.D. Wilson, T.S. Mang, M. Cooper and H. Stoll, Use of Photodynamic 
Therapy for the Treatment ofExtensive Basal Cell Carcinomas, Facial 
Plast. Surg., 6 (1989) 185-189. 
[49] D.G. Pennington, M. Waner and A. Knox, Photodynamic Therapy for 
Multiple Skin Cancers, Plast. Reconstr. Surg., 82 (1988) 1067-1071. 
[50] J.S. McCaughan Jr., J.T. Guy, W. Hicks, L. Laufman, T.A. Nims and 
J. Walker, Photodynamic Therapy for cutaneous and subcutaneous 
malignant eoplasms, Arch. Surgery, 124 (2), (1989) 211-216. 
[51] D. Gilson, D. Ash, I. Drirer, J.W. Feather and S. Brown, Therapeutic 
ratio of Photodynamic Therapy in the Treatment of Superficial 
Tumours of Skin and Subcutaneous Ti sues in Man, Br. J. Cancer, 68 
(1988) 665-667. 
[52] D.J. Gross, M. Waner, R.H. Schosser and S.M. Dinehart, Squamous 
Cell Carcinoma of the Lower Lip Involving aLarge Cutaneous Surface, 
Photodynamic Therapy as an Alternative Therapy, Arch. Dermatol., 
126 (1990) 1148-1150. 
[53]T.J. Dougherty, Photoradiation Therapy for Cutaneous and 
Subcutaneous Malignancies, J. Invest. Dermatol., 77 ( 1981 ) 122-124. 
[54] G. Bandieramonte, R. Marchesini, E.Melloni, C. Andreoli, S. di Pietro, 
P. Spinelli, G. Fava, F. Zunino and H. Emanuelli, Laser Phototherapy 
Following HpD Administration i Superficial Neoplastic Lesions, 
Tumouri, 70 (1984) 327-334. 
[55] M. Shuh, U.O. Nseyo, W.R. Potter, T.L. Dao and T.J. Dougherty, 
Photodynamic Therapy for Palliation of Locally Recurrent Breast 
Carcinoma, J. Clin. Oncol., 5 (1987) 1766-1770. 
[56] V.G. Schweitzer, D. Visscher, Photodynamic Therapy for Treatment 
of AIDS-related Oral Kaposi's Sarcoma, Otolaryngol. Head Neck 
Surg., 102 (1990) 639~49. 
[57] J.L. McCullogh, G.D. Weinstein, J.L. Douglas and M.W. Berns, 
Photosensitizers in dermatology, Photochem. Photobiol., 46 (1987) 
77-82. 
[58] G.D. Weinstein, J.L. McCullough, J.S. Nelson and M.W. Berns, Low 
dose Photofrin I! photodynamic therapy of psoriasis, J. Invest. 
Dermatol., 96 ( 1991 ) 573. 
[59] A.L. Abramson, MJ. Shikowitz, V.M. Mullooly, B.M. Steinberg, C.A. 
Amelia and H.R. Rothstein, Clinical effects of photodynamic therapy 
on recurrent laryngeal papillomas, Arch. Otolaryngol. Head Neck 
Surg., 118 (1992) 25-29. 
[60] O. Santoro, G. Bandieramonte, E. Melloni, R. Marchesini, F. Zunino, 
P. Lepera and G. De Palo, Photodynamic therapy by topical mete- 
tetraphenylporphinesulphonate tetrasodium salt administration i
superficial basal cell carcinomas, Cancer Res., 50 (1990) 4501--4503. 
[61] J.C. Kennedy and R.H. Pottier, Endogenous protoporphyrin IX, a 
clinically useful photosensitizer for photodynamic therapy, J. 
Photochem. Photobiol. B: Biol., 14 (1992) 275-292. 
[62] P. Wolf, E. Rieger and H. Kerl, Topical photodynamic therapy with 
endogeneous porphyrins after application of 5-aminolevulinic a id, Z 
Am. Acad. Derm., 28(1) (1993) 17-21. 
[63] F. Cairnduff, M.R. Stringer, E.J. Hudson, D.V. Ash and S.B. Brown, 
Superficial photodynamic therapy with topical 5-aminolevulinic a id 
for superficial primary and secondary skin cancer, Br.J. Cancer, 69 
(1994) 605-608. 
[64] K. Svanberg, T. Anderson, D. Killander, I. Wang, U. Stenram, 
S. Andersson-Engels, R. Berg, J. Johansson and S. Svanberg, 
Photodynamic therapy of non-melanoma malignant turnouts of the 
skin using topical &aminolevulinic acid sensitization and laser 
irradiation, Br. J. DermatoL, 130 (1994) 743-751. 
[65] H. Lui, N. Kollias, J. Wimberly, S. Salasche, D. McLean and R. 
Anderson, Photodynamic therapy of nonmelanoma skin cancer with 
5-aminolevulinic a id and visible light: a clinical and histological 
study, Proc. Ann. Meet. Am. Soc. Photobiol., (1994) 59s, 71s. 
12 J.J. Schuitmaker tal. /Journal of Photochemistry and Photobiology B: Biology 34 (1996) 3-12 
[66] S.D. Shanler, W. Wan, J.E. Whitaker, T.S. Mang, C. Jones, B.D. 
Wilson, H. Stoll and A.R. Oseroff, Photodynamic therapy with topical 
&aminolevulinic acid for treatment of cutaneous carcinomas and 
cutaneous T-cell lymphoma, J. Invest. Dermatol., 101 (1993) 406a. 
[67] P. Wolf, R. Fink-Puches, L. Cerroni and H. Kerl, Photodynamic 
therapy for mycosisfungoides after topical photosensitisation with 5- 
aminolevulinic a id, J. Am. Acad. Derm., 31 (1994) 678--680. 
[68] D.R. Gnepp (ed.), Pathology of the Head and Neck, Churchill, 
Livingstone, New York, 1988, pp. 266-284. 
[69] J.G. Batsakis (ed.), Tumours of the Head and Neck. Clinical and 
Pathological Considerations, 2nd edn., William and Wilkins, 
Baltimore, M.D., 1979, pp. 144-177. 
[70] D.P. Slaughter, H.W. Southwick and W. Smejkal, "Field 
cancerization' in oral stratified squamous epithelium: clinical 
implications of multicentric origin, Cancer, 6 (1953) 963-968. 
[71] N. de Vries, Second primary tumours in laryngeal cancer, Acta 
Otorhinolaryngol.-Belg., 46 (1992) 153-159. 
[72] N. de Vries, I. van de Waal and G.B. Snow, Multiple primary tumours 
in oral cancer, Int. J. Oral Maxillofac. Surg., 15 (1986) 85-87. 
[73] R. Pasche, M. Savary and Ph. Monnier, Multiple squamous cell 
carcinoma of the upper digestive and lower respiratory tracts: 
methodology of endoscopic screening, Acta Endoscopica, 11 ( 1981 )
277-291. 
[74] A.G. Wile, A. Dahlman A, R.G. Bums and M.W. Betas, Laser 
photoradiation therapy of cancer following hematoporphyrin 
sensitization, Lasers Surg. Med., 2 (1982) 107-127. 
[75] A. Dahlman, A.G. Wile, R.G. Bums, R. Mason, F.M. Johnson and 
M.W. Betas, Laser photoradiation therapy of cancer, Cancer Res., 43 
(1983) 430-434. 
[76] L.I. Grossweiner, J.H. Hill, R.V. Lobraico, Photodynamic therapy of 
head and neck squamous cell carcinoma: optical dosimetry and clinical 
trial, Photochem. Photobiol., 46 (1987) 911-917. 
[77] G.S. Keller, D.R. Doiron and G.U. Fisher, Photodynamic therapy in 
otolaryngology- Head and Neck Surgery, Arch. Otolaryngol., 111 
(1985) 758-761. 
[78] D.E. Schuller, J.S. McCaughan and R.P. Rock, Photodynamic therapy 
in head and neck cancer, Arch. Otolaryngol., 111 (1985) 351-355. 
[79] J.L. Gluckman, Hematoporphyrin photodynamic therapy: Is theretruly 
a future in head and neck oncology? Reflections of a 5 year experience, 
Laryngoscope. 101 ( 1991 ) 36-42. 
[80] C. Freche and S. De Corbiere, Use of photodynamic therapy in the 
treatment ofvocal cord carcinoma, J. Photochem. PhotobioL B: Biol., 
6 (1990) 291-296. 
[81 ] Ph. Monnier, M. Savary, Ch. Fontolliet, G. Wagnieres, A. Chatelain, 
P. Comaz, Ch. Depeursinge and H. van den Bergh, Photodetection a d 
photodynamic therapy of "early" squamous cell carcinoma of the 
pharynx, oesophagus and tracheo-bronchial tree, Lasers Med. Sci., 5 
(1990) 149-169. 
[82] K. Moghissi, K. Dixon, E. Hudsun and M. Stringer, Photodynamic 
therapy (PDT) of Oesophageal cancer, Lasers Med. Sci., 10 (1995) 
67-71. 
[83] M.A. Biel, Photodynamic therapy and the treatment of primary 
malignancies of the head and neck, in 5th. Int. Photodynamic 
Association Biennial Meeting, September 21-24, 1994, FL, USA, 
Abstract 100. 
[84] B. Overholt, M. Panjehpour, E. Tefftelar and M. Rose, Photodynamic 
therapy for treatment ofearly adenocarcinoma in Barret's esophagus, 
Gastrointest. Endoscop., 39, (1) (1993) 73-76. 
[ 85 ] H.G. Schmidt, R.H. Riddell, B. Walter, D.B. Skinner and J.F. Riemann, 
Dysplasia in Barret's esophagus, J. Cancer Res. Clin. Oncol., 110 
(1985) 145-152. 
[86] H. Ban', T. Dix, D. Roberts and N. Shepard, Eradication of high grade 
dysplasia in columnar lined (Barret's) oesophagus by photodynamic 
therapy with oral 5-aminolevulinic a id and 630 nm light, Gut, 35, 
(Suppl. 5), (1994) 7. 
[ 87 ] J.F. Savary, Ch. Fontolliet, D. Braichotte, Ph. Monnier and H. van den 
Bergh, Detection by fluorescence microscopy of the localization and 
time dependent mTHPC. Distribution in biopsies of bronchi, 
oesophagus and pharynx, in 5th Int. Photodynamic Association 
Biennial Meeting, September 21-24, 1994, FL, USA, Abstract, p. 37. 
[ 88 ] J.F. Savary, Ch. Fontolliet, D. Braichotte, Ph. Monnier and H. van den 
Bergh, First clinical results after photodynamic treatment of early 
squamous cell carcinomas ofthe oesophagus, bronchi and mouth with 
meta-tetrahydroxyphenyl chlorin (m-THPC), in 5th Int. Photodynamic 
Association Biennial Meeting, September 21-24, 1994, FL, USA, 
Abstract 27. 
[89] Ph. Monnier, J.F. Savary, G. Wagnieres, H. van den Bergh, J. Mizeret 
and Ch. Fontolliet, Green light (514 nm) irradiation for the prevention 
of complications in PDT of early squamous cell carcinomas of the 
oesophagus, in5th Int. Photodynamic Association Biennial Meeting, 
September 21-24, 1994, FL, USA, Abstract 28. 
[90] M.G. Dilkes and M.L. DeJode, m-THPC mediated PDT. Experience 
and thoughts after 17 treatments, in D.A. Cortese (ed.) 5th Int. 
Photodynamic Association Biennial Meeting, Proc. SPIE., 2371 
(1995) 256--261. 
[91 ] W.E. Grant, C. Hopper, A.J. MacRobert, P.M. Speight and S.G. Bown, 
Photodynamic therapy of oral cancer: photosensitization with systemic 
aminolaevulinic a id, Lancet, 342 (1993) 147-148. 
[92] C. Hopper, K. Fan, W.E. Grant, P.M. Speight and S.G. Bown, 
Photodynamic therapy using 5-aminolaevulinic acid in oral 
malignancy and premalignancy, in D.A. Cortese (ed.), 5th Int. 
Photodynamic Association Biennial Meeting, Proc. SPIE, 2371 
(1995) 254-255. 
[93] M.A. Biel, Photodynamic therapy and the treatment of neoplastic 
diseases of the larynx, Laryngoscope, 104 (1994) 399-403. 
[94] MA. Biel, Photodynamic tyherapy as an adjuvant intraoperative 
treatment ofrecurrent head and carcinomas, in5th Int. Photodynamic 
Association Biennial Meeting, September 21-24, 1994 FL, USA, 
Abstract 101. 
[95] A.L. Abramson, M.J. Shikowitz, V.M. Mullooly, B.M. Steinberg and 
R.B. Hyman, Variable light dose effects on photodynamic therapy for 
laryngeal papillomas, Arch. OtolaryngoL Head and Neck Surg., 120 
(1994) 852-855. 
[96] J. Feyh, A. Gutmann and A. Leunig, Photodynamic tberapy in head 
and neck surgery, Laryngo Rhino Otol., 72 (1993) 273-278. 
[97] J. Feyh, Photodynamic therapy of malignant and nonmalignant 
tumours in head and neck surgery. Results of a clinical study, in 5th 
Int. Photodynamic Association Biennial Meeting, September 21-24 
1994, FL, USA, Abstract 103. 
[98] T.J. Dougherty, Photodynamic therapy for early stage lung cancer, 
Chest, 102 (5), (1992) 1314-1315. 
[ 99 ] J.G. Levy, The preclinical and clinical development of Photofrin® and 
benzoporphyrin derivative: A reflection on opportunities and 
challenges, J. Photochem. Photobiol. B: Biol., 30 (1995) 79-82. 
